Bronchial Dieulafoy disease: A case report and literature review Authors: Zhenggong Wang, Yunfeng He, Miao Huang, Xiongjun Zhang, Rui Ma Published: 2026 ABSTRACT AbstractBronchial Dieulafoy disease (BDD) is a rare disease characterized by abnormal dilation or malformation of the submucosal artery of the bronchus. This disease features a low incidence, but its bleeding is rapid and occult, which easily leads to delayed diagnosis, endangers life, and is difficult to handle clinically. Currently, its diagnosis mainly relies on bronchoscopy and angiography, and treatment methods include endoscopic treatment, interventional embolization, and surgical operation. There are still many unsolved problems regarding the exact pathogenesis, treatment timing, treatment method selection, and long-term management of this disease. This article reports a case of a 54-year-old male patient who was admitted due to repeated hemoptysis for 2 years. During hospitalization, bronchoscopy was performed, and the result showed a nodule in the anterior segment of the right upper lung (brown vascular shadow seen on NBI). In view of the patient's repeated hemoptysis and high risk of massive bleeding, Bronchial Artery Embolization (BAE) was performed for him after obtaining the patient's consent. The operation successfully embolized the patient's diseased bronchial artery, and the patient did not experience hemoptysis again after the operation. During the follow-up period outside the hospital, the patient did not have hemoptysis again.Keywords: Bronchial Dieulafoy disease, Hemoptysis, Bronchoscopy, BAE, Diagnosis and treatment progress, Case report Background BDD is a rare disease that may cause fatal massive hemoptysis. Its essence is the presence of abnormally thick and tortuous arteries (usually branches of the bronchial artery) in the submucosa of the bronchial wall. These blood vessels do not distribute parallel to the bronchial wall but penetrate the bronchial cartilage rings at an almost vertical angle to reach the submucosa, with only a thin layer of normal mucosa covering the surface, which can rupture and bleed due to various reasons [1]. Due to the occult nature of its lesions and the easy missed diagnosis by routine examinations, it often leads to delayed diagnosis, difficult treatment, and high mortality. Since the disease was first described in 1995, the number of case reports worldwide is still very limited [2]. Traditionally, its diagnosis largely depends on bronchoscopy and angiography. Pathological examination is the gold standard for the diagnosis of BDD, but there is some controversy in practical application because biopsy may induce fatal massive hemoptysis [3]. In recent years, with the continuous development of interventional radiology and thoracic surgery technology, BAE and lobectomy have become the main treatment methods. But there are still controversies regarding the selection of treatment timing, the determination of treatment methods, and the strategies for long-term management. This article reports a case of BDD, and the patient has agreed to the publication of this report. Simultaneously, based upon systematic literature review, this article aims to comprehensively expound the epidemiological characteristics, pathophysiological mechanism, clinical and imaging manifestations, diagnostic key points, treatment plan selection and prognosis of this disease, thereby enhancing clinicians' vigilance and diagnosis and treatment level of this disease. Case presentation The patient reported repeated hemoptysis (1-2 ml each time) in the past 2 years, and the hemoptysis worsened in the past 3 months. He came to our hospital for further treatment. The patient underwent “radical resection of lung cancer” more than 10 years ago, and received radiotherapy and chemotherapy after the operation, with no other special medical history. No obvious abnormalities were found in the physical examination on admission. Preliminary Diagnosis: 1. Hemoptysis, 2. Personal history of lung malignant tumor, 3. Hepatic space-occupying lesion. After admission, relevant examinations were completed: No obvious abnormalities were found in blood routine, blood biochemistry, urine routine, stool routine, sputum smear and other examinations. In order to further understand the lumen situation and clarify the cause of hemoptysis, the patient completed bronchoscopy, which showed: Nodule in the anterior segment of the right upper lung (Fig. 1). Chest CT showed tortuous right bronchial artery (Fig. 2, Fig. 3). Considering the patient's repeated hemoptysis and high risk of massive hemoptysis, bronchial arteriography was performed after the patient signed the informed consent form. The results showed that the right bronchial artery was thickened and tortuous, with a rich peripheral vascular bed (Fig. 4A). During the operation, it was difficult to super-select the coated guide wire + microcatheter into the distal end of the right bronchial artery, so 3 peripheral ciliated embolization coils were used to embolize the main trunk of the right bronchial artery under fluoroscopy. After embolization, the tortuous vascular malformation at the periphery disappeared on angiography (Fig. 4B). The patient did not have hemoptysis again after the operation, and there was no recurrence during the 5-month follow-up after the operation. A,Nodule in the anterior segment of the right upper lung.B.,Brown vascular shadow seen on NBI. Chest CT showed tortuous right bronchial artery (12/31/2025). Chest CT showed tortuous right bronchial artery (11/04/2024). A, Pre-embolization angiography.B. Postoperative angiography. Discussion In this case, the patient presented with repeated hemoptysis, a nodule in the anterior segment of the right upper lung was found by bronchoscopy, and brown vascular shadow was shown on NBI. Considering the patient's previous history of malignancy and bleeding risk, mucosal biopsy was performed on the middle segment of the right lung instead of bronchoscopic biopsy at the aforementioned site (Fig. 5). In terms of treatment, the patient had repeated hemoptysis and high risk of massive hemoptysis, so BAE was performed. The patient did not have hemoptysis again after the operation. Based on the patient's relevant auxiliary examinations, BDD was finally considered. Middle segment of the right lung: Necrotic material, no malignant lesions observed. Origin of disease Dieulafoy's disease is relatively common in the gastrointestinal tract, also known as submucosal gastric aneurysm or Dieulafoy's ulcer. The classic gastrointestinal Dieulafoy disease was first reported in 1884 by French surgeon Dieulafoy as bleeding from persistent-caliber submucosal gastric arteries [4]. BDD is relatively rare, and it was first described in the respiratory system by Sweerts et al. [2] in 1995. Up to recent years, the number of cases reported in the global literature is limited, with a total of less than 100 cases reported. Epidemiological data show that BDD can occur in all age groups, from infants to the elderly, but it is more common in middle-aged and elderly patients, with more male patients than female patients (2:1), and the incidence in the right lung is higher than that in the left lung (2.5:1) [[4], [5], [6], [7]]. Etiology and pathophysiology of BDD The etiology and pathogenesis of BDD have not been clearly elucidated to date, and the disease is generally attributed to the following factors:①Congenital dysplasia of bronchial artery/pulmonary artery [8]; ②Chronic airway inflammation or injury [9]; ③Normal vascular variation [4]; ④Others: Tuberculous inflammatory injury, long-term smoking, traction and dilation of bronchial artery, and microbe-vascular dynamic imbalance [6,10]. At present, some scholars in China have proposed to classify BDD into endoluminal type: The abnormal artery breaks through the bronchial wall and runs under the mucosa and protrudes into the cavity; Extraluminal type: Abnormal arteries run along the submucosa of the bronchus. Under bronchoscopy, local mucosa can be seen as mounds or flat warty protrusions. If the location is superficial, vascular-like pulsation can be observed [11]. Clinical manifestations and diagnostic challenges of BDD The clinical manifestations of BDD are diverse, and the most common symptom is hemoptysis, whose severity ranges from blood-tinged sputum to life-threatening massive hemoptysis. Some patients may present with cough, shortness of breath, chest discomfort, or be found through examination, while the vast majority of patients have no infection signs such as fever and purulent sputum, which helps to initially differentiate from common causes of hemoptysis such as bronchiectasis and pneumonia [6,12]. It is worth noting that during the intermittent period of hemoptysis attacks, patients lack typical symptoms, which poses a great challenge to the early identification of the disease [13]. With respect to physical examination, apart from the shock and anemia signs such as respiratory distress, pale complexion, accelerated heart rate and decreased blood pressure caused by massive hemoptysis in BDD, specific manifestations are often difficult to be detected by auscultation of the lungs. The significant contrast between this “asymptomatic” state and “sudden fatal massive hemoptysis”, as well as the lack of specificity of lung signs, more fully indicate that the clinical manifestations of this disease are complex and accidental. When clinicians face patients with unknown etiology, especially those with repeated hemoptysis, they should include this disease in the differential diagnosis. The diagnosis of BDD is extremely challenging, and its difficulties are mainly reflected in the lack of specificity of imaging examinations, the limitations of bronchoscopy, and misdiagnosis due to insufficient clinical understanding. Routine imaging examinations, such as chest X-ray and chest CT, are usually difficult to have specific findings [14]. Therefore, the main value of imaging examinations in the diagnosis of BDD is to exclude other common lung diseases, such as lung cancer, bronchiectasis or tuberculosis, rather than direct diagnosis. Bronchoscopy is an important tool for the diagnosis of BDD. Typical endoscopic manifestations: smooth papillary, nodular or ridge-like submucosal protrusions. The surface mucosa is usually intact, covered with yellowish-white exudates to form a “white cap” appearance, and in a few cases, there is a slight vascular pulsation [14]. At present, some scholars classify BDD according to the results of bronchoscopy: ①Mucosal protruding type; ②Bleeding and thrombus type; ③Vascular tortuosity type; ④Other special types [10]. Nonetheless, there is no consensus on the classification method of BDD at present. The best time for bronchoscopy is during the active bleeding period or shortly after bleeding, when the lesion is easier to be found. However, these manifestations overlap with the endoscopic manifestations of benign endobronchial tumors or vascular malformations. In addition, the diagnostic efficacy is limited by the experience of the examiner. During the intermission of hemoptysis, the lesion may only present as a slight mucosal bulge or a completely normal appearance under bronchoscopy, which is easily overlooked by inexperienced examiners [1]. CTA and DSA are the keys to confirm the diagnosis and formulate the diagnosis and treatment plan. The typical imaging features of BDD include: Abnormally thickened and tortuous vascular shadow originating from the bronchial artery, with unnatural vascular course, and the end may be suddenly truncated instead of gradually tapering normally; In some cases, blood vessels protruding into the bronchial lumen showing nodular changes can be seen, which is of great significance for preoperative evaluation and avoiding risky biopsy [15,16]. Bronchial artery CTA can clearly show the abnormal blood vessels in or adjacent to the bronchial wall. Before BAE, CTA can pre-identify the opening position, course, and collateral circulation of the target blood vessel, thereby significantly improving the accuracy and success rate of embolization treatment, while reducing the risk of surgery-related complications. DSA could be able to dynamically and clearly present the morphology and hemodynamic characteristics of the diseased blood vessels, such as vascular tortuosity, dilation, aneurysmal changes or contrast medium extravasation, which helps to find abnormal bronchial arteries and provide an accurate path for subsequent embolization treatment [17,18]. Pathological diagnosis is the gold standard for the diagnosis of BDD, which is characterized by tortuous, dilated, and dysplastic arteries in the bronchial submucosa, protruding or directly communicating with the lumen [5]. In clinical practice, this diagnosis relies on surgically resected specimens or autopsy specimens, and not all cases can be confirmed by pathology. So the diagnosis tends to be based on typical bronchoscopy and angiography findings [4]. In recent years, the application of narrow-band imaging bronchoscopy, autofluorescence bronchoscopy and endobronchial ultrasonography has provided powerful new tools for diagnosis, enabling clinicians to obtain more information regarding lesion characterization [19,20]. As a rare pulmonary vascular malformation, BDD requires careful differential diagnosis from various other vascular diseases responsible for hemoptysis. First, differentiation from bronchopulmonary artery fistula mainly relies on imaging features. CTA identifies characteristic abnormal shunting vessels in bronchopulmonary artery fistula, whereas BDD only presents with tortuous and dilated regional vessels or contrast extravasation without vascular shunt signs; bronchoscopy serves as the pivotal modality to distinguish these two entities [21]. Second, BDD should be differentiated from pulmonary artery pseudoaneurysm. CTA directly demonstrates communication between the aneurysm and the trunk or branches of the pulmonary artery in pseudoaneurysm, while BDD originates from the bronchial arterial system with no direct anatomical connection to the pulmonary artery, enabling differential diagnosis based on this distinction [22]. Finally, hereditary hemorrhagic telangiectasia (HHT) needs to be excluded from BDD. Patients with HHT generally have a positive family history and multiple telangiectases involving the skin, oronasal mucosa, lungs, liver and gastrointestinal tract, which facilitates discrimination from BDD [23]. Beyond vascular disorders, BDD must also be differentiated from common nonvascular causes of hemoptysis including bronchiectasis, pulmonary malignancy and pulmonary tuberculosis to reduce missed or erroneous diagnoses and avoid unnecessary invasive procedures. In most instances, differential diagnosis between BDD and the above conditions can be accomplished by integrating medical history, clinical manifestations, imaging findings and laboratory data [24]. Treatment strategies and advances BAE At present, the treatment of BDD has not been completely unified, mainly including conservative treatment, bronchoscopic treatment, BAE, surgical treatment, etc. As a minimally invasive interventional treatment technology, BAE has become the preferred and mainstream method for dealing with massive hemoptysis, especially bleeding caused by rare causes such as BDD. The immediate hemostasis rate of BAE is as high as 70%∼99% [25]. Its principle is to super-selectively place a catheter into the diseased artery under the guidance of DSA, and then inject embolization materials (such as embolization microspheres, gelatin sponge particle embolic agents, coils, etc.) to block blood flow and reduce vascular pressure, so as to achieve the purpose of hemostasis. For BDD, its pathological basis is that the abnormally dilated and twisted arteries under the bronchial mucosa are directly exposed or only covered with a thin layer of epithelium. Once ruptured, the bleeding is often large and fierce, and the effect of drug treatment is limited. However, due to the deep location and limited scope of the lesion, and patients usually have other underlying diseases, the surgical risk is high. Cha et al. [18] study showed that BAE for clinically suspected BDD can obtain good results, with a technical and clinical success rate of 100%, and no surgery-related complications occurred after the operation; The recurrence rate was 6% during an average follow-up of 491.9 days. With the progress of technology, it is reported that the two-year hemostasis rate of BAE is as high as 90% [26]. With its minimally invasive, safe, effective and repeatable operation characteristics, BAE has shown irreplaceable value in controlling such life-threatening hemoptysis. This creates a valuable time window for stabilizing the patient's condition, avoiding fatal blood loss, and for subsequent possible surgical operations [27]. Although BAE has a significant immediate effect in controlling acute hemoptysis of BDD, it still has the risks of procedure-related complications and postoperative recurrence. The most serious and highly vigilant complication of BAE is ectopic embolization, especially accidental embolization of the anterior spinal artery may lead to paraplegia. This requires the operator to perform super-selective intubation angiography during the operation, or use larger diameter embolization materials (such as coils) for embolization at the proximal end, so as to avoid tiny particles from flowing into the spinal artery [28]. In addition, other potential complications include allergy to anesthetics and iodinated contrast media, post-embolization syndrome (manifested as chest pain, fever, foreign body sensation on swallowing, hiccup, etc.), intercostal skin necrosis, esophagobronchial fistula, arterial dissection and operative site hemorrhage. Most of these adverse events can be improved with active symptomatic treatment once they occur intraoperatively or postoperatively.Recurrence may be caused by a variety of factors, common reasons include vascular variation, incomplete embolization, and the formation of collateral circulation, and its long-term recurrence rate can reach 10∼20% [29]. In addition, as a palliative treatment, BAE does not eliminate the abnormal artery under the bronchial mucosa itself, and the blood vessel may rupture and bleed again under the inducement of blood pressure fluctuation, cough, etc. Therefore, strict case selection, careful preoperative evaluation, standardized operation procedures, and complete emergency plans are the keys to ensuring the safe and effective implementation of BAE. Overall, for patients with recurrent BDD, BAE can be repeated if necessary according to the condition; If interventional therapy fails repeatedly, or the patient's bleeding cannot be controlled, surgical treatment should be actively considered. Emergency management and endoscopic therapy The most dangerous clinical manifestation of BDD is sudden and fatal massive hemoptysis. In the process of rescuing BDD massive hemoptysis, the primary task is to maintain airway patency and circulatory stability, which is the basis for saving the patient's life. First, the patient should be placed in the affected side lying position to prevent blood from flowing into the healthy side; Ensure airway opening by oxygen inhalation or tracheal intubation; Establish venous access and initiate initial hemostatic therapy with vasopressin and tranexamic acid. In cases of active massive hemorrhage complicated by hypotension and abrupt hemoglobin drop, implement rapid fluid resuscitation and transfuse packed red blood cells and plasma to reverse hemorrhagic shock.However, conservative management including fluid resuscitation, blood transfusion, antitussive, hemostatic and anti-infective medications is generally ineffective.If conditions permit, bronchoscopy can be used to remove the accumulated blood in the airway, or balloon compression hemostasis can be used to create conditions for subsequent treatment [30]. Bronchoscopic treatment is the first-line therapy for BDD, with the advantages of minimal trauma and repeatable operation. During active bleeding, if exposed blood vessels or bleeding points are found by bronchoscopy, local injection of drugs (such as ice normal saline, epinephrine, thrombin,etc.) can be tried. Besides, bronchoscopic argon plasma coagulation, ablation therapy, electrocautery, cryotherapy, laser and other methods have been reported to treat BDD [19,20,31]. However, once the BDD blood vessel ruptures, there will be a large amount of bleeding and unclear vision, and the effect of these treatment methods needs further study. It is recommended that the operation be performed by experienced doctors under the premise of ensuring safety. Endoscopic treatment has limitations such as perforation, incomplete hemostasis, and high recurrence rate. There are case reports of bleeding after BDD biopsy, conventional endoscopic hemostasis was tried, but the effect was limited, and further intervention was still needed [29]. This may be related to the fact that endoscopic treatment only deals with the surface or part of the blood vessels, but fails to completely eradicate the deep abnormal vascular structure [19]. Overall, endoscopic treatment is an important part of the comprehensive management of BDD, especially suitable for patients who need acute hemostasis and stable condition. However, its radical cure has certain limitations, and it usually needs to be combined with BAE or surgical operation to achieve the best treatment effect. Surgical treatment strategies Surgical treatment (lobectomy or segmentectomy) is a definitive method for radical cure of BDD [32]. When BAE fails, hemoptysis recurs, or the lesion is localized and the patient's cardiopulmonary function can tolerate the operation, surgical resection becomes a key treatment option [15]. Studies have shown that BAE and lobectomy are the main treatment strategies. Nonetheless, hemoptysis may recur after BAE, while lobectomy is a curative method [32]. Liu Xu et al. [29]discovered that once hemoptysis occurs after BDD biopsy, the mortality rate is extremely high. When conventional endoscopic hemostasis, balloon dilation compression hemostasis, vascular intervention and other methods are ineffective, timely and decisive resection of the bleeding target lung segment is helpful to rescue the patient and improve the prognosis. A study on pediatric BDD found that among 16 patients treated with BAE and/or lobectomy, only 1 patient had hemoptysis again after two BAE and right upper lobectomy, but no recurrence occurred after medical conservative treatment, which shows that surgery is an effective final option for refractory cases [33]. Up to now, surgery has always been the main definite treatment method, and the success rate reported currently is close to 100% [14,34]. Hence, for patients with ineffective interventional therapy or contraindications, surgery provides a clear opportunity for cure, which can not only confirm the diagnosis but also resect the lesion [35]. Accurate localization of the lesion before surgery, fine operation during surgery, and definite hemostasis are the keys to the success of the operation. In normal conditions, this requires the combination of CTA and bronchoscopy, and sometimes staining localization technology. With the wide application of minimally invasive thoracoscopic technology, the surgical trauma of BDD has been significantly reduced, and the patient's postoperative recovery speed has been accelerated. Thoracoscopic surgery avoids the large incision of traditional open surgery, reduces the degree of postoperative pain and the occurrence of complications, and has become the preferred surgical method for modern thoracic surgery to handle such diseases. For BDD with extensive or multiple lesions, more complex lung resection surgery may be required. In this case, a multidisciplinary team is needed to jointly evaluate the benefits and risks of the operation. Although most BDD lesions are relatively localized and suitable for lobectomy, a few cases may involve multiple lobes or bronchi, or the blood supply range of the malformed blood vessels is wide. At this time, more complex surgical procedures such as double lobectomy, sleeve resection, or even pneumonectomy may be required [36]. At present, five categories of surgical procedures for BDD have been reported:①Sublobar resection: this procedure consists of wedge resection and anatomic segmentectomy. Clinical studies have verified that pulmonary wedge resection is indicated for lesions located subpleurally in the peripheral lung; anatomic segmentectomy is suitable when lesions are confined within the bronchus of a single pulmonary segment with parenchymal involvement limited to that segment. This approach features minimal surgical trauma and mild impairment of pulmonary function, yet it is time-consuming and demands proficient thoracoscopic anatomical dissection skills from surgeons, making it inappropriate for patients with multifocal lesions involving multiple segments [19].②Lobectomy: mainly indicated for lesions extending to the lobar bronchial orifice with multisegmental involvement or multiple feeding arteries, as well as cases with recurrent bleeding after failed BAE. The core operative steps are as follows: first dissect and ligate the main pulmonary artery of the affected lobe to avoid intraoperative massive hemorrhage; subsequently divide the pulmonary vein and dissect the lobar bronchus. The bronchus is transected approximately 1 cm proximal to the lesion, the bronchial stump is sealed with a stapler, and routine hilar lymph node dissection is performed [8].③ Bronchial sleeve resection: a rarely performed operation primarily reserved for central-type BDD in children and young adults [37].④Isolated ligation of abnormal vessels: a narrow-indication procedure exclusively for selected critically ill patients who have severely compromised baseline pulmonary function precluding pulmonary resection and refractory hemorrhage after BAE. Additional prerequisites include fixed lesion location, abnormal vessels confined to the peribronchial mediastinum without submucosal bronchial invasion (only endobronchial bulging), and the bulk of the vessel remaining entirely outside the bronchial lumen [19,38].⑤Emergency pneumonectomy: an emergency salvage operation indicated for patients with diffuse multifocal BDD involving an entire lung complicated by recurrent life-threatening massive hemoptysis uncontrollable via lobectomy; or critically ill patients with bilateral BDD presenting with life-threatening unilateral massive hemoptysis whose contralateral lung retains sufficient reserve to tolerate pneumonectomy [19,38]. In addition, surgery is accompanied by anesthesia risks and possible postoperative complications, such as pulmonary infection, respiratory insufficiency, bronchopleural fistula, etc. Although minimally invasive technology has significant advantages, comprehensive evaluation is still required when making decisions to minimize surgical risks and improve the long-term quality of life of patients. Prognosis The prognosis of BDD is closely related to a variety of factors, among which early diagnosis and timely and effective intervention are the keys to determining the survival rate of patients. The clinical manifestations of BDD are not specific and are easily misdiagnosed as bronchiectasis, tuberculosis, or lung cancer. Therefore, for patients with hemoptysis, bronchoscopy, CTA or DSA should be prioritized, and blind biopsy should be avoided during bronchial examination, which is of vital significance for avoiding catastrophic complications and improving prognosis. BAE cannot solve the problem once and for all. For patients who relapse after BAE treatment, measures such as repeated embolization or surgical intervention can be considered. In addition to the timing and method of treatment, the patient's own individual factors also have a significant impact on the prognosis. For BDD patients, factors such as age, general condition, and severity of bleeding should be comprehensively evaluated to formulate individualized treatment plans and follow-up strategies, thus maximizing the improvement of prognosis. Long-term follow-up and management after BDD treatment are extremely important, aiming to monitor rebleeding, evaluate treatment effects, and deal with recurrence in a timely manner. It is recommended to re-examine 3-6 months after the initial treatment, and the re-examination methods mainly include bronchoscopy, CTA, etc. As for patients with recurrent BDD hemoptysis, treatment strategies should be formulated according to specific conditions. First, repeated BAE embolization is selected, and embolization materials can be considered to be replaced during the operation, such as using embolization materials of different diameters or combining these materials. If BAE treatment fails, surgical treatment should be considered. At present, most of the cases reported in the literature come to see a doctor due to hemoptysis. The natural history of completely asymptomatic BDD is very limited, and preventive intervention itself has risks. Thus, clinical decisions need to carefully weigh the immediate risks of intervention and the potential possibility of massive hemoptysis in the future. For such patients, close follow-up may be a reasonable initial choice [37]. Conclusions BDD is a rare disease, but it may cause fatal massive hemoptysis. Its diagnosis needs to comprehensively consider the patient's medical history and the results of relevant examinations such as bronchoscopy, CTA, DSA, and pathology, but blind biopsy should be avoided. In terms of treatment, BAE has a very significant immediate hemostasis effect and relatively small trauma, which is the first-line choice for treatment. For some cases, endoscopic treatment can be used as a supplementary or bridging method. For patients with complex anatomical structures, failed embolization treatment, or rebleeding, surgical lobectomy is still an indispensable final guarantee measure. Funding Not applicable. CRediT authorship contribution statement Zhenggong Wang: Writing – original draft, Writing – review & editing. Yunfeng He: Supervision. Miao Huang: Software. Xiongjun Zhang: Supervision. Rui Ma: Supervision. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Contributor Information Zhenggong Wang, Email: wang15287525541@outlook.com. Yunfeng He, Email: 1357396743@qq.com. Miao Huang, Email: 2315329761@qq.com. Xiongjun Zhang, Email: 375395413@qq.com. Rui Ma, Email: 1476775493@qq.com. References